<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2587">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03330353</url>
  </required_header>
  <id_info>
    <org_study_id>2017p001603</org_study_id>
    <nct_id>NCT03330353</nct_id>
  </id_info>
  <brief_title>Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy</brief_title>
  <acronym>PMPSP</acronym>
  <official_title>Functional Assessment of the Melanopsin-Containing Retinal Ganglion Cells in Progressive Supranuclear Palsy Using Chromatic Pupillometry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NeurOptics Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific aim of this study is to investigate rod, cone and melanopsin driven pupillary&#xD;
      light response in individuals with progressive supranuclear palsy (PSP), age-matched healthy&#xD;
      controls and individuals with other neurodegenerative diseases using chromatic pupillometry,&#xD;
      with special interest in assessing melanopsin-driven post-illumination pupil response (PIPR)&#xD;
      as an identifier for PSP.&#xD;
&#xD;
      The study addresses the following hypotheses:&#xD;
&#xD;
        1. Chromatic pupil responses, including rod/cone-driven rapid phase constriction and&#xD;
           melanopsin-driven PIPR, are reduced in subjects with PSP compared to age-matched normal&#xD;
           healthy control subjects,&#xD;
&#xD;
        2. Pupil parameters of the melanopsin-driven PIPR are abnormal in PSP subjects without&#xD;
           supranuclear palsy, which is indicative of a subclinical physiological deficit of the&#xD;
           OPN in the early stages of PSP.&#xD;
&#xD;
      If these hypotheses are upheld, chromatic pupillometry to measure the PIPR promises to be a&#xD;
      reliable in vivo, non-invasive, convenient and inexpensive technique to detect asymptomatic&#xD;
      pupillomotor impairment in advance of diagnostic oculomotor signs and deterioration of&#xD;
      cognitive function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In 1963, Richardson, Steele and Olszewski published a landmark clinical report on 8 cases of&#xD;
      supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia and&#xD;
      established the syndrome of heterogeneous system degeneration as a clinicopathological entity&#xD;
      now known as PSP. The disease has a characteristic onset in the sixth decade (range 45 to 75&#xD;
      years) with some combination of impaired balance, abrupt falls, visual disturbances, slurred&#xD;
      speech, dysphasia and vague changes in personality.&#xD;
&#xD;
      Slowing of voluntary vertical saccades, either down, up or both are a diagnostic marker of&#xD;
      PSP and later impairment of voluntary horizontal saccades are characteristic in more than&#xD;
      half of the cases. However, a proportion of PSP patients do not demonstrate these eye signs&#xD;
      for a year or more after the onset of the disease.&#xD;
&#xD;
      This pilot study will use chromatic pupillometry to determine whether such a novel&#xD;
      methodology may be used as an objective in vivo identifier of PSP. The rationale for the&#xD;
      study is based in part on:&#xD;
&#xD;
        1. Clinicopathological correlation between the key clinical signs of a supranuclear gaze&#xD;
           palsy with pathological verification that the degenerative process affects the pretectum&#xD;
           and rostral midbrain,&#xD;
&#xD;
        2. The melanopsin-signaling pathway from ipRGCs (intrinsically photosensitive retinal&#xD;
           ganglion cells) in the eye projects to the OPN (olivary pretectal nucleus) in the&#xD;
           midbrain,&#xD;
&#xD;
        3. Chromatic pupillometry is a non-invasive technique suitable for elderly subjects with or&#xD;
           without dementia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Pupil Constriction</measure>
    <time_frame>2 years</time_frame>
    <description>The smallest pupil size following light stimulation. This parameter primarily represents rapid phase extrinsic ipRGC activity driven by rods and cones through synaptic input.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-illumination pupil response (PIPR)</measure>
    <time_frame>2 years</time_frame>
    <description>Measured pupil diameter over a period of 20 seconds, from 10 to 30 seconds after the offset of light stimulation.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">56</enrollment>
  <condition>PSP - Progressive Supranuclear Palsy</condition>
  <condition>PD - Parkinson's Disease</condition>
  <condition>AD - Alzheimer's Disease</condition>
  <condition>ALS (Amyotrophic Lateral Sclerosis)</condition>
  <arm_group>
    <arm_group_label>Neurodegenerative Diseases</arm_group_label>
    <description>Individuals with neurodegenerative diseases</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pupillometry</intervention_name>
    <description>Use of pupillometry to assess melanopsin-light pathway in patients with neurodegenerative diseases</description>
    <arm_group_label>Neurodegenerative Diseases</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects diagnosed with PSP and age-matched control subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Individuals that meet the clinical criteria for PSP. Core features include:&#xD;
&#xD;
               -  Recurrent falls and unsteady gait&#xD;
&#xD;
               -  Axial and nuchal rigidity&#xD;
&#xD;
               -  Pseudobulbar palsy&#xD;
&#xD;
               -  Bilateral lid retraction&#xD;
&#xD;
               -  Supranuclear vertical gaze palsy&#xD;
&#xD;
               -  Atrophy of the midbrain tegmentum (the hummingbird sign on brain MRI,&#xD;
&#xD;
          2. Individuals that fit the criteria for the second PSP phenotype (which resembles PD)&#xD;
             that has asymmetric findings, tremors and poor responses to treatment with Levodopa,&#xD;
&#xD;
          3. Individuals that meet the clinical criteria for PD with:&#xD;
&#xD;
               -  Progressive bradykinesia&#xD;
&#xD;
               -  Postural instability and frequent falls&#xD;
&#xD;
               -  Festinating gait with loss of associated movements&#xD;
&#xD;
               -  Cogwheel rigidity and mask-like face&#xD;
&#xD;
               -  Rest tremor,&#xD;
&#xD;
          4. Individuals who carry a diagnosis of Alzheimer' disease who present with progressive&#xD;
             impairment of memory and cognitive domains such as language and visuospatial&#xD;
             perception.&#xD;
&#xD;
        Diagnoses will be confirmed by the review of health/medical records of patients recruited&#xD;
        from the Frontotemporal Disorders Unit clinic. In the case of participants recruited from&#xD;
        research studies, diagnoses will be confirmed by the review of the research diagnoses&#xD;
        indicated on the individuals' research records.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Individuals who are frail or in questionable health,&#xD;
&#xD;
          2. Individuals with cataracts or with posterior pole ocular pathology such as age-related&#xD;
             macular degeneration and optic neuropathies, including open angle high intraocular&#xD;
             pressure glaucoma,&#xD;
&#xD;
          3. Individuals with photophobia (i.e., painful light sensitivity) when exposed to bright&#xD;
             light, including those with ophthalmological conditions such as keratitis (herpes&#xD;
             simplex), uveitis or Achromatopsia,&#xD;
&#xD;
          4. Individuals with advanced dementia with inability to sit erect, hold the eyes open,&#xD;
             incontinence,&#xD;
&#xD;
          5. Individuals with epilepsy,&#xD;
&#xD;
          6. Individuals diagnosed with major depression or other severe psychiatric disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shirley H Wray, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shirley H Wray, MD, PhD</last_name>
    <phone>617-726-5539</phone>
    <email>wray@helix.mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley H Wray, MD, PhD, FRCP</last_name>
      <phone>617-726-5539</phone>
      <email>wray@helix.mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>September 19, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Shirley Wray</investigator_full_name>
    <investigator_title>Professor of Neurology, Harvard Medical School</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Coded data will be shared with co-investigators</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT03330353/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT03330353/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

